Table 3.
Molecular factors | Prognostic implication in MSI-H CRC (molecular alteration) | Ref. |
HSP110 | Favorable (high expression of mutant HSP110/low expression of wild-type HSP110) | Dorard et al[59], 2011 |
Kim et al[96], 2014 | ||
Beta2- microglobulin | Favorable (mutation of beta2-microglobulin) | Kloor et al[54], 2007 |
Tikidzhieva et al[143], 2012 | ||
Myosin 1a | Unfavorable (low expression of myosin 1a) | Mazzolini et al[53], 2012 |
CDX2/CK20 | Unfavorable (loss of CDX2/CK20 expression) | Kim et al[149], 2013 |
SMAD4 | Favorable (high expression of SMAD4) | Isaksson-Mettavainio et al[150], 2012 |
CIMP | Unfavorable (CIMP-H) | Bae et al[87], 2011 |
LINE-1 | Unfavorable (low LINE-1 methylation level) | Rhee et al[162], 2012 |
CIMP: CpG island methylator phenotype; CIMP-H: CIMP-high; CRC: Colorectal cancer; LINE-1: Long interspersed nucleotide element-1; MSI-H: Microsatellite instability-high; HSP110: Heat shock protein 110 kDa; CDX2: Caudal-type homeobox 2; CK20: Cytokeratin 20; SMAD4: SMAD family member 4.